Evolving Management Options for Alopecia Areata: Clinical Burden, Cost-Effective Care, and Emerging Treatments




This CME activity for ACCME credit is provided by Integrity Continuing Education, Inc.

This CE activity for ACPE credit is jointly provided by Global Education Group and Integrity Continuing Education, Inc.


This activity is supported by an educational grant from Pfizer, Inc.


The hair loss that occurs in patients with alopecia areata (AA) imposes a significant psychological burden on the over 300,000 US individuals affected by the disease each year. Traditionally, AA management has been limited to the off-label use of various treatments, many of which can be associated with significant side effects and often provide only limited relief. As understanding of AA pathophysiology has evolved, we have witnessed the development of a number of novel targeted therapies. Foremost among these are multiple Janus kinase (JAK) inhibitors, one of which has just been approved by the FDA.

Join our esteemed faculty for a review of the recently approved and emerging JAK inhibitor therapies for AA. This activity is complemented with case-based learning and faculty round-table discussions to help providers achieve better outcomes for their patients with AA.


Brett King, MD
Associate Professor of Dermatology
Yale School of Medicine
New Haven, Connecticut

Eric Cannon, PharmD, FAMCP
Chief Pharmacy Officer
Murray, Utah

Dana McCormick, RPh, FAMCP
Director of Pharmacy
Blue Cross Blue Shield
Grapevine, Texas

Release date: January 18, 2023
Expiration date: January 18, 2024
Estimated time to complete activity: 60 minutes

This educational activity has been designed for community pharmacists, specialty pharmacists, and healthcare professionals in allergy, immunology, dermatology, and managed care who manage patients with AA.


Upon completion of this educational activity, participants should be able to:

  • Outline the pathophysiology and clinical burden of AA
  • Review clinical data on emerging agents for AA to determine their potential placement in the treatment landscape
  • Identify the pharmacoeconomic factors associated with emerging AA therapies

There are no fees for participating and receiving CME credit for this activity. During the period of January 18, 2023, through January 18, 2024, participants must:

  • Read the learning objectives
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better. For pharmacist/ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity. Credit cannot be issued after 60 days.




Physician Continuing Education

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education

Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

Credit Designation

Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number – 0530-9999-22-111-H01-P)

This is a knowledge-based activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

For information about ACPE accreditation of this activity, please contact Global Education Group at (303) 395-1782 or cme@globaleducationgroup.com.


Integrity Continuing Education, Inc. and Global Education Group require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE/CME activity:

Eric Cannon, PharmD, FAMCP has no real or apparent conflicts of interest to disclose.

Brett King, MD
Advisory Boards, Consultant: AbbVie, AltruBio Inc, Almirall, AnaptysBio, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol Myers Squibb, Concert Pharmaceuticals Inc, Eli Lilly and Company, Equillium, Horizon Therapeutics, Incyte Corp, Janssen Pharmaceuticals, LEO Pharma, Otsuka/Visterra Inc, Pfizer, Inc., Regeneron Pharmaceuticals, Sanofi Genzyme, TWi Biotechnology Inc, Viela Bio
Speaker: AbbVie, Eli Lilly and Company, Incyte, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme
Investigator: AnaptysBio, Arena Pharmaceuticals, Concert Pharmaceuticals Inc, Eli Lilly and Company, Pfizer, Inc.

Dana McCormick, RPh, FAMCP has no real or apparent conflicts of interest to disclose.

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager Reported Financial Relationship
Olivia Benevento Nothing to disclose
Lindsay Borvansky Nothing to disclose
NyQwayah Brown Nothing to disclose
Ashley Cann Nothing to disclose
Stefani Chiarolanza Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Brittany Puster Nothing to disclose
Lauren Sinclair Nothing to disclose
Patima Tanapat, PhD Nothing to disclose

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest